dalfampridine (Ampyra)
Jump to navigation
Jump to search
Indications
- improve walking in multiple sclerosis
Contraindications
- moderate-severe renal insufficiency
Dosage
Pharmacokinetics
- eliminated by kidney
Adverse effects
Mechanism of action
- active ingredient is 4-aminopyridine
- blocks K+ channels in demyelinated neurons, restoring conductivity
More general terms
References
- ↑ FDA NEWS RELEASE, Jan. 22, 2010 FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm
- ↑ 2.0 2.1 FDA MedWatch, July 23, 2012 Ampyra (dalfampridine): Drug Safety Communication - Seizure Risk for Multiple Sclerosis Patients http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm313055.htm
- ↑ Egeberg MD, Oh CY, Bainbridge JL. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Clin Ther. 2012 Nov;34(11):2185-94 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23123001
- ↑ Goodman AD, Brown TR, Edwards KR et al A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20976768
- ↑ Ampyra, Acorda Therapeutics, Inc, Physician Resources http://ampyra-hcp.com/hcp/physician_resources/